Abrysvo RSV vaccine in NYC and Long Island

Abrysvo is an RSV vaccine with two different uses: preventing RSV lower respiratory tract disease in eligible adults, and helping protect a newborn through vaccination during pregnancy. The adult and pregnancy decisions use different criteria. An RSV test or treatment for an active infection is a separate service. The vaccine prompts the recipient to make antibodies against RSV. During pregnancy, some antibodies cross the placenta and help protect the baby during the first months after birth.

FDA labeling includes adults 60 and older and adults 18–59 at increased risk, plus pregnancy at 32–36 weeks. CDC currently recommends adult RSV vaccination for everyone 75 and older and adults 50–74 at increased risk. FDA approval for a younger adult does not by itself establish a CDC recommendation. For pregnancy, CDC specifies 32 weeks 0 days through 36 weeks 6 days, generally September–January in the continental United States. Only Abrysvo is used for the maternal RSV pathway.

FDA labeling includes adults 60 and older and adults 18–59 at increased risk, plus pregnancy at 32–36 weeks. CDC currently recommends adult RSV vaccination for everyone 75 and older and adults 50–74 at increased risk. FDA approval for a younger adult does not by itself establish a CDC recommendation. For pregnancy, CDC specifies 32 weeks 0 days through 36 weeks 6 days, generally September–January in the continental United States.

No. CDC currently recommends one adult RSV vaccine dose rather than yearly vaccination. A previous dose should not be repeated just because another RSV season begins. Maternal vaccination and infant antibodies have separate seasonal eligibility rules.

Coverage for abrysvo rsv vaccine depends on the exact plan, age or risk indication, product, administering site, and benefit rules. Ask the insurer and selected clinic to confirm the vaccine or antibody, administration, and any separate visit or form charge. A listed insurance name or a covered visit is not confirmation that this product will be paid.

Contact the selected clinic before traveling and name abrysvo rsv vaccine, the recipient’s age, and any date or brand requirement. Ask whether it has the correct product and can administer it for this indication. A general walk-in or appointment slot does not reserve a dose or establish coverage.

Most babies need one of these protection pathways. CDC uses maternal Abrysvo at 32 weeks 0 days–36 weeks 6 days, generally September–January, or an eligible first-season infant antibody. An infant may need an antibody if maternal vaccination was absent, unknown, or less than 14 days before birth. Prior maternal RSV vaccination in another pregnancy also changes the plan because repeat maternal doses are not currently recommended.

Abrysvo is neither a live vaccine nor an mRNA vaccine. It contains recombinant RSV proteins that stimulate an immune response. Its adult and pregnancy uses have different eligibility rules; vaccine type alone does not establish that it is appropriate for you.

Yes, when the vaccines are indicated for that person. Adult RSV vaccine can be given at the same visit as other adult vaccines. Maternal Abrysvo can be given with Tdap, flu or COVID vaccine, but its pregnancy window remains 32–36 weeks and seasonal timing still matters. The clinician reviews prior reactions and the possibility of more short-term side effects.

Egg is not listed as an ingredient in the Abrysvo prescribing information. Its RSV proteins are produced using a mammalian cell system. Tell the clinician about your specific allergies: absence of egg does not rule out a severe reaction to another ingredient or a previous dose.